S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(-1.03%) $82.99
Gas
(-1.16%) $1.619
Gold
(-0.56%) $2 334.10
Silver
(-0.91%) $27.29
Platinum
(0.41%) $925.90
USD/EUR
(-0.12%) $0.934
USD/NOK
(-0.06%) $11.02
USD/GBP
(-0.18%) $0.799
USD/RUB
(0.00%) $92.17

Realaus laiko atnaujinimai Smith & Nephew plc [SN.L]

Birža: LSE Pramonė: Medical Devices
Upcoming Earnings Alert

2 days till quarter result
(bmo 2024-05-01)

Expected move: +/- 4.95%

Atnaujinta26 bal. 2024 @ 18:38

1.72% £ 981.00

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:38):

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...

Stats
Šios dienos apimtis 4.29M
Vidutinė apimtis 3.62M
Rinkos kapitalizacija 8.58B
EPS £0 ( 2024-02-27 )
Kita pelno data ( £0 ) 2024-05-01
Last Dividend £18.38 ( 2023-03-30 )
Next Dividend £0 ( N/A )
P/E 40.88
ATR14 £0.504 (0.05%)

Tūris Koreliacija

Ilgas: 0.35 (neutral)
Trumpas: -0.51 (weak negative)
Signal:(63.072) Neutral

Smith & Nephew plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Smith & Nephew plc Koreliacija - Valiuta/Žaliavos

The country flag 0.70
( moderate )
The country flag 0.73
( moderate )
The country flag -0.28
( neutral )
The country flag 0.79
( moderate )
The country flag 0.30
( neutral )
The country flag -0.65
( moderate negative )

Smith & Nephew plc Finansinės ataskaitos

Annual 2023
Pajamos: £5.55B
Bruto pelnas: £3.82B (68.82 %)
EPS: £0.300
FY 2023
Pajamos: £5.55B
Bruto pelnas: £3.82B (68.82 %)
EPS: £0.300
FY 2022
Pajamos: £5.22B
Bruto pelnas: £3.68B (70.47 %)
EPS: £0.250
FY 2021
Pajamos: £5.21B
Bruto pelnas: £3.67B (70.40 %)
EPS: £0.598

Financial Reports:

No articles found.

Smith & Nephew plc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
£12.91
(N/A)
£0
(N/A)
£18.38
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)

Smith & Nephew plc Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.49 - good (84.92%) | Divividend Growth Potential Score: 4.99 - Stable (0.29%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend £3.45 1993-05-10
Last Dividend £18.38 2023-03-30
Next Dividend £0 N/A
Payout Date 2023-05-17
Next Payout Date N/A
# dividends 64 --
Total Paid Out £440.59 --
Avg. Dividend % Per Year 1.26% --
Score 4.16 --
Div. Sustainability Score 8.49
Div.Growth Potential Score 4.99
Div. Directional Score 6.74 --
Next Divdend (Est)
(2024-06-18)
£0 Estimate 1.28 %
Dividend Stability
0.10 Bad
Dividend Score
4.16
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield
1993 £0 0.00%
1994 £0 0.00%
1995 £0 0.00%
1996 £0 0.00%
1997 £0 0.00%
1998 £0 0.00%
1999 £0 0.00%
2000 £0 0.00%
2001 £0 0.00%
2002 £0 0.00%
2003 £0 0.00%
2004 £0 0.00%
2005 £0 0.00%
2006 £0 0.00%
2007 £0 0.00%
2008 £0 0.00%
2009 £0 0.00%
2010 £0 0.00%
2011 £0 0.00%
2012 £0 0.00%
2013 £0 0.00%
2014 £0 0.00%
2015 £0 0.00%
2016 £0 0.00%
2017 £0 0.00%
2018 £26.91 1.93%
2019 £28.49 1.99%
2020 £29.73 1.62%
2021 £27.12 1.73%
2022 £31.31 2.40%
2023 £18.38 1.64%
2024 £0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
ROOF.L Dividend Knight 2023-08-03 Quarterly 3 1.92%
HHV.L Dividend Knight 2023-06-29 Semi-Annually 19 3.83%
AVON.L Dividend Junior 2023-08-10 Semi-Annually 33 1.69%
VCAP.L Dividend Knight 2023-09-14 Semi-Annually 4 3.56%
MRCH.L Dividend King 2023-07-06 Quarterly 53 3.07%
DLN.L Dividend Knight 2023-09-07 Semi-Annually 32 1.77%
SHG.L Dividend Knight 2023-11-02 Semi-Annually 4 0.91%
IHP.L Dividend Knight 2023-06-08 Semi-Annually 7 1.08%
BOCH.L Dividend Junior 2023-05-04 Insufficient data to determine frequency 2 1.10%
OCN.L Dividend Knight 2023-05-18 Annually 19 3.96%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.04741.5009.0510.00[0 - 0.5]
returnOnAssetsTTM0.02631.2009.1210.00[0 - 0.3]
returnOnEquityTTM0.05031.500-0.552-0.828[0.1 - 1]
payoutRatioTTM1.243-1.00010.00-10.00[0 - 1]
currentRatioTTM1.7750.8006.134.90[1 - 3]
quickRatioTTM0.5690.800-1.359-1.087[0.8 - 2.5]
cashRatioTTM0.1331.500-0.372-0.558[0.2 - 2]
debtRatioTTM0.309-1.5004.85-7.28[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM0.6952.009.7710.00[0 - 30]
freeCashFlowPerShareTTM0.2072.009.9010.00[0 - 20]
debtEquityRatioTTM0.591-1.5007.64-10.00[0 - 2.5]
grossProfitMarginTTM0.7011.0001.6441.644[0.2 - 0.8]
operatingProfitMarginTTM0.1231.0009.549.54[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1971.000-0.0159-0.0159[0.2 - 2]
assetTurnoverTTM0.5560.8009.637.70[0.5 - 2]
Total Score8.49

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM40.781.0005.980[1 - 100]
returnOnEquityTTM0.05032.50-0.355-0.828[0.1 - 1.5]
freeCashFlowPerShareTTM0.2072.009.9310.00[0 - 30]
dividendYielPercentageTTM2.851.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM0.6952.009.7710.00[0 - 30]
payoutRatioTTM1.2431.50010.00-10.00[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1101.0009.760[0.1 - 0.5]
Total Score4.99

Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.